# China NMPA Drug Inspection - Shangqiu Jinma Pharmaceutical Co., Ltd. - Corydalis analgesic tablets

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/shangqiu-jinma-pharmaceutical-co-ltd/04c83b9b-f0c3-4161-b29a-8278c98d45ea/
Source feed: China

> China NMPA drug inspection for Shangqiu Jinma Pharmaceutical Co., Ltd. published December 25, 2019. Drug: Corydalis analgesic tablets. The Sichuan Provincial Drug Administration (NMPA) released an announcement on December 25, 2019, outlining the findings 

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Sichuan Provincial Drug Administration's Sichuan Provincial Drug Quality Bulletin (Issue 9, 2019)
- Company Name: Shangqiu Jinma Pharmaceutical Co., Ltd.
- Publication Date: 2019-12-25
- Drug Name: Corydalis analgesic tablets
- Inspection Finding: [Test] (Auramine O)
- Action Taken: The matter has been investigated and dealt with in accordance with laws and regulations, and the products have been ordered to be suspended from sale and use, recalled, and the reasons for non-compliance investigated and thoroughly rectified.
- Summary: The Sichuan Provincial Drug Administration (NMPA) released an announcement on December 25, 2019, outlining the findings from its 2019 drug sampling inspection program. These inspections, conducted across drug production, distribution, and usage units in various cities and prefectures throughout 2019, aimed to ensure product quality and safety within the province.The regulatory body identified 26 batches of non-compliant drugs from multiple manufacturers, including Bazhong Huikang Pharmaceutical Co., Ltd., Jilin Jibang Pharmaceutical Co., Ltd., Hebei Jinzhuan Pharmaceutical Co., Ltd., and Shangqiu Jinma Pharmaceutical Co., Ltd. Non-compliance issues primarily related to specific quality attributes, such as incorrect properties, presence of impurities (e.g., salicylic acid, auramine), inadequate identification, and deviations in the quantitative determination of active ingredients. These findings were based on criteria established in the Chinese Pharmacopoeia (2015 Edition) and relevant national supplementary inspection methods.As a result, implicated companies were directed to implement several mandatory actions. These included immediately suspending sales and use of the affected products, initiating comprehensive recalls, conducting thorough investigations into the underlying causes of the non-compliance, and executing robust rectification measures to address the identified problems.

Company: https://www.globalkeysolutions.net/companies/shangqiu-jinma-pharmaceutical-co-ltd/09164103-f1e9-49f4-b7e6-ac686e466a75/